Postmenopausal Osteoporosis With High Fracture Risk Therapeutics
1. Yorvipath patent expiration
Treatment: Treatment of hypoparathyroidism in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS PHARMA BONE | Prodrug comprising a drug linker conjugate |
Apr, 2031
(5 years from now) | |
| US11890326 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11918628 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12453778 | ASCENDIS PHARMA BONE | NA |
Sep, 2037
(11 years from now) | |
| US12403182 | ASCENDIS PHARMA BONE | NA |
Nov, 2042
(16 years from now) | |
| US12295989 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11857603 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| US11590207 | ASCENDIS PHARMA BONE | Dosage regimen for a controlled-release PTH compound |
Sep, 2037
(11 years from now) | |
| US11759504 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 09, 2029 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
NCE-1 date: 09 August, 2028
Market Authorisation Date: 09 August, 2024
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
